29 research outputs found
Culture of mouse peritoneal macrophages with mouse serum induces lipid bodies that associate with the parasitophorous vacuole and decrease their microbicidal capacity against Toxoplasma gondii
Characterization of a new class of blue-fluorescent lipid droplet markers for live-cell imaging in plants
Lipid Body Organelles within the Parasite Trypanosoma cruzi: A Role for Intracellular Arachidonic Acid Metabolism
Lipid BodyâPhagosome Interaction in Macrophages during Infectious Diseases: Host Defense or Pathogen Survival Strategy?
Natural Schistosoma mansoni Infection in the Wild Reservoir Nectomys squamipes Leads to Excessive Lipid Droplet Accumulation in Hepatocytes in the Absence of Liver Functional Impairment
Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog
Conselho Nacional de Desenvolvimento CientĂfico e TecnolĂłgico (CNPq)Indole alkaloids ellipticine (1), cryptolepine triflate (2a), rationally designed 11-(4-piperidinamino)cryptolepine hydrogen dichloride (2b) and olivacine (3) (an isomer of 1) were evaluated in vitro against Plasmodium falciparum and in vivo in'Plasmodium berghei-infected mice. 1-3 inhibited P. falciparum (IC50 1 > 2a > 3). In vitro toxicity to murine macrophages was evaluated and revealed selectivity indices (SI) of 10-12 for 2a and SI> 2.8 x 102 for 1, 2b and 3.1 administered orally at 50 mg/kg/day was highly active against P. berghei (in vivo inhibition compared to untreated control (IVI) = 100%, mean survival time (MST)> 40 days, comparable activity to chloroquine control). 1 administered orally and subcutaneously was active at 10 mg/kg/day (IVI = 70-77%; MST= 27-29 days). 3 exhibited high oral activity at >= 50 mg/kg/day (IVI =90-97%, MST= 23-27 days). Cryptolepine (2a) administered orally and subcutaneously exhibited moderate activity at 50 mg/kg/day (IVI =43-63%, MST= 24-25 days). At 50 mg/kg/day, 2b administered subcutaneously was lethal to infected mice (MST= 3 days) and moderately active when administered orally (IVI =45-55%, MST = 25 days). 1 and 3 are promising compounds for development of antimalarials. (C) 2012 Elsevier GmbH. All rights reserved.2017176Conselho Nacional de Desenvolvimento CientĂfico e TecnolĂłgico (CNPq)MCT/INPA/INPAPRONEX/FINEP [023/2009]Science and Technology Foundation of Portugal [PTDC/SAU-FAR/114864/2009, PEst-OE/SAU/UI4013/2011]Conselho Nacional de Desenvolvimento CientĂfico e TecnolĂłgico (CNPq)CNPq [CNPq 555665/2009-7, CNPq 555669/2009-2]CNPq [554317/2010-9]PRONEX/FINEP [023/2009]Science and Technology Foundation of Portugal [PTDC/SAU-FAR/114864/2009, PEst-OE/SAU/UI4013/2011